Nanogen Licenses Schizophrenia Biomarkers From Aussie Groups | GenomeWeb
NEW YORK (GenomeWeb News) — Nanogen has licensed genetic markers related to schizophrenia and to antipsychotic drug response from Australia’s Co-Operative Research Centre for Diagnostics and Queensland University of Technology.
Nanogen said it will use the markers to develop diagnostics for schizophrenia and “related conditions,” and said that some of the markers may be useful in predicting adverse drug reactions. The company said these markers have been linked to the disease “in a number of clinical studies.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.